JP2012500197A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500197A5 JP2012500197A5 JP2011523005A JP2011523005A JP2012500197A5 JP 2012500197 A5 JP2012500197 A5 JP 2012500197A5 JP 2011523005 A JP2011523005 A JP 2011523005A JP 2011523005 A JP2011523005 A JP 2011523005A JP 2012500197 A5 JP2012500197 A5 JP 2012500197A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- cells
- cell
- rassf1a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 32
- 229940002612 prodrug Drugs 0.000 claims description 31
- 239000000651 prodrug Substances 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 102000016397 Methyltransferase Human genes 0.000 claims description 8
- 108060004795 Methyltransferase Proteins 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000011987 methylation Effects 0.000 claims description 3
- 238000007069 methylation reaction Methods 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 1
- -1 carbazole compound Chemical class 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- DWMBXHWBPZZCTN-HSZRJFAPSA-N (3r)-3,5-dimethyl-3-(4-methylpent-3-enyl)-11h-pyrano[3,2-a]carbazol-9-ol Chemical class OC1=CC=C2C3=CC(C)=C4O[C@@](CCC=C(C)C)(C)C=CC4=C3NC2=C1 DWMBXHWBPZZCTN-HSZRJFAPSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- DWMBXHWBPZZCTN-UHFFFAOYSA-N mahanine Natural products OC1=CC=C2C3=CC(C)=C4OC(CCC=C(C)C)(C)C=CC4=C3NC2=C1 DWMBXHWBPZZCTN-UHFFFAOYSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18905908P | 2008-08-15 | 2008-08-15 | |
| US61/189,059 | 2008-08-15 | ||
| PCT/US2009/004681 WO2010019271A1 (en) | 2008-08-15 | 2009-08-14 | Fluorescent regulators of rassf1a expression and human cancer cell proliferation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014105150A Division JP2014148545A (ja) | 2008-08-15 | 2014-05-21 | Ｒａｓｓｆ１ａ発現およびヒト癌細胞増殖の蛍光調節剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012500197A JP2012500197A (ja) | 2012-01-05 |
| JP2012500197A5 true JP2012500197A5 (cg-RX-API-DMAC7.html) | 2013-05-09 |
Family
ID=41279343
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523005A Pending JP2012500197A (ja) | 2008-08-15 | 2009-08-14 | Ｒａｓｓｆ１ａ発現およびヒト癌細胞増殖の蛍光調節剤 |
| JP2014105150A Pending JP2014148545A (ja) | 2008-08-15 | 2014-05-21 | Ｒａｓｓｆ１ａ発現およびヒト癌細胞増殖の蛍光調節剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014105150A Pending JP2014148545A (ja) | 2008-08-15 | 2014-05-21 | Ｒａｓｓｆ１ａ発現およびヒト癌細胞増殖の蛍光調節剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10457639B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2323982B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2012500197A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102186820B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE547403T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009282451B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0917411A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2734225A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010019271A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| NZ601784A (en) | 2010-03-08 | 2014-08-29 | Monsanto Technology Llc | Polynucleotide molecules for gene regulation in plants |
| US8637679B2 (en) | 2011-03-11 | 2014-01-28 | Council Of Scientific And Industrial Research | Process for the isolation of organic compounds useful for the treatment of cancer |
| WO2013040057A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| AU2012308686B2 (en) | 2011-09-13 | 2018-05-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| EP2756086B1 (en) | 2011-09-13 | 2018-02-21 | Monsanto Technology LLC | Methods and compositions for weed control |
| US9416363B2 (en) | 2011-09-13 | 2016-08-16 | Monsanto Technology Llc | Methods and compositions for weed control |
| WO2013040117A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
| EP2855680B8 (en) | 2012-05-24 | 2020-04-15 | Monsanto Technology LLC | Compositions and methods for silencing gene expression |
| AU2013371825B2 (en) | 2013-01-01 | 2019-10-24 | A.B. Seeds Ltd. | Methods of introducing dsRNA to plant seeds for modulating gene expression |
| US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
| BR112015022797A2 (pt) | 2013-03-13 | 2017-11-07 | Monsanto Technology Llc | método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo |
| EP2971185A4 (en) | 2013-03-13 | 2017-03-08 | Monsanto Technology LLC | Methods and compositions for weed control |
| WO2014151317A1 (en) * | 2013-03-15 | 2014-09-25 | Rush University Medical Center | Methods for treating cancer |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| MX359191B (es) | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
| US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
| UA120426C2 (uk) | 2013-11-04 | 2019-12-10 | Монсанто Текнолоджі Елелсі | Композиція та спосіб для боротьби з членистоногими паразитами та зараженням шкідниками |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| BR112016016337A2 (pt) | 2014-01-15 | 2017-10-03 | Monsanto Technology Llc | Composição e métodos para controlar crescimento, desenvolvimento ou a capacidade de reprodução de uma planta, e para sensibilizar uma planta para um herbicida inibidor de epsps |
| CN110506752B (zh) | 2014-04-01 | 2022-02-18 | 孟山都技术公司 | 用于控制虫害的组合物和方法 |
| EP3158067B1 (en) | 2014-06-23 | 2020-08-12 | Monsanto Technology LLC | Compositions and methods for regulating gene expression via rna interference |
| WO2015200539A1 (en) | 2014-06-25 | 2015-12-30 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| US10378012B2 (en) | 2014-07-29 | 2019-08-13 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
| UA124255C2 (uk) | 2015-01-22 | 2021-08-18 | Монсанто Текнолоджі Елелсі | Інсектицидна композиція та спосіб боротьби з leptinotarsa |
| UY36703A (es) | 2015-06-02 | 2016-12-30 | Monsanto Technology Llc | Composiciones y métodos para la administración de un polinucleótido en una planta |
| AU2016270913A1 (en) | 2015-06-03 | 2018-01-04 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
| US10173978B2 (en) | 2015-08-05 | 2019-01-08 | Georgetown University | Small molecule androgen receptor inhibitors and methods of use thereof |
| WO2018230556A1 (ja) * | 2017-06-12 | 2018-12-20 | 昇平 宮田 | 抗癌剤及びその使用 |
| CN107266356B (zh) * | 2017-07-25 | 2020-06-26 | 山西省生物研究院有限公司 | 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2235815A1 (de) * | 1972-07-21 | 1974-01-31 | Bayer Ag | Polyazofarbstoffe |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU643141B2 (en) | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| GB9215361D0 (en) | 1992-07-20 | 1992-09-02 | Wellcome Found | Heterocyclic compounds |
| DE69431470T2 (de) | 1993-07-26 | 2003-08-14 | Eisai Co., Ltd. | Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring |
| JP3690825B2 (ja) * | 1993-07-26 | 2005-08-31 | エーザイ株式会社 | 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体 |
| CA2186412A1 (en) | 1995-10-31 | 1997-05-01 | Katherine S. Takaki | Ethylamino carbazole melatonergic agents |
| DE69830513T2 (de) | 1997-12-22 | 2006-03-16 | Bayer Pharmaceuticals Corp., West Haven | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN |
| AU3840000A (en) * | 1999-04-20 | 2000-11-02 | Meiji Seika Kaisha Ltd. | Tricyclic compounds |
| KR20020069215A (ko) | 1999-12-16 | 2002-08-29 | 아사히 가세이 가부시키가이샤 | 신규한 치환기를 갖는 3환성 화합물 |
| WO2001083452A1 (en) | 2000-04-28 | 2001-11-08 | Asahi Kasei Kabushiki Kaisha | Novel tricyclic compounds |
| US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
| EP1352650B1 (en) | 2000-12-18 | 2012-03-07 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
| AU2002228316A1 (en) * | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JPWO2002074306A1 (ja) | 2001-03-19 | 2004-07-08 | 旭化成ファーマ株式会社 | 脂肪肝治療薬 |
| GB0319151D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| EP1768663A1 (en) | 2004-06-29 | 2007-04-04 | Jadolabs Gmbh | Carbazole-derived pharmaceutical compositions |
| ATE381540T1 (de) | 2004-08-18 | 2008-01-15 | Ciba Sc Holding Ag | Oximesther-fotoinitiatoren |
| ITMI20051523A1 (it) * | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
| GB2443588B (en) | 2005-09-01 | 2010-04-21 | Council Scient Ind Res | A pharmaceutical composition useful for the treatment of prostate cancer |
| CN1807413B (zh) | 2005-09-28 | 2010-05-05 | 中国医学科学院医药生物技术研究所 | 咔唑磺酰胺衍生物及其制备方法 |
| AU2006300877A1 (en) * | 2005-10-13 | 2007-04-19 | Orchid Research Laboratories Limited | Heterocyclic compounds as pSTAT3/IL-6 inhibitors |
| US20100130579A1 (en) * | 2006-10-23 | 2010-05-27 | Georgetown University | Cancer therapy |
| IL186935A0 (en) | 2006-10-31 | 2008-02-09 | Veridex Llc | Prostate cancer field effect analysis methods and kits |
| WO2009086472A2 (en) | 2007-12-28 | 2009-07-09 | John Wayne Cancer Institute | Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer |
| EP2268612B1 (en) | 2008-03-24 | 2014-08-20 | Novartis AG | Arylsulfonamide-based matrix metalloprotease inhibitors |
-
2009
- 2009-08-14 US US13/059,183 patent/US10457639B2/en active Active
- 2009-08-14 AT AT09789145T patent/ATE547403T1/de active
- 2009-08-14 EP EP09789145A patent/EP2323982B1/en not_active Not-in-force
- 2009-08-14 BR BRPI0917411A patent/BRPI0917411A2/pt not_active IP Right Cessation
- 2009-08-14 CN CN2009801406819A patent/CN102186820B/zh not_active Expired - Fee Related
- 2009-08-14 CA CA2734225A patent/CA2734225A1/en not_active Abandoned
- 2009-08-14 WO PCT/US2009/004681 patent/WO2010019271A1/en not_active Ceased
- 2009-08-14 AU AU2009282451A patent/AU2009282451B2/en not_active Ceased
- 2009-08-14 EP EP20120152000 patent/EP2484666A1/en not_active Withdrawn
- 2009-08-14 JP JP2011523005A patent/JP2012500197A/ja active Pending
-
2014
- 2014-05-21 JP JP2014105150A patent/JP2014148545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500197A5 (cg-RX-API-DMAC7.html) | ||
| US9138418B2 (en) | Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles | |
| US12227503B2 (en) | Compositions and methods for modulating hair growth | |
| ES2665539T3 (es) | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 | |
| NZ588583A (en) | Novel lipid formulations for nucleic acid delivery | |
| Sun et al. | Anti-miRNA oligonucleotide therapy for chondrosarcoma | |
| JP2019511491A5 (cg-RX-API-DMAC7.html) | ||
| US11976092B2 (en) | RNA nanostructures, methods of making, and uses thereof | |
| US20110034545A1 (en) | Double-stranded lipid-modified rna having high rna interference effect | |
| EP3791897A1 (en) | Hsp90 inhibitor drug conjugates | |
| JP2021502346A5 (cg-RX-API-DMAC7.html) | ||
| CN110573166B (zh) | 用于癌症治疗的吉西他滨衍生物 | |
| Navarro et al. | Defined covalent attachment of three cancer drugs to DNA origami increases cytotoxicity at nanomolar concentration | |
| US20220372493A1 (en) | Rna nanoparticle for liver cancer treatment | |
| WO2017193460A1 (zh) | 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法 | |
| JP2025507982A (ja) | 活性分子送達に利用可能な分解性リポソーム及びそのナノ複合体 | |
| Srinivas | The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges | |
| US20240115596A1 (en) | Compositions and methods for treating sars-cov-2 infection | |
| TW201620504A (zh) | 局部投與用脂質複合體之新穎製造方法及使用該脂質複合體之抗腫瘤劑 | |
| US20230358726A1 (en) | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer | |
| US20240035035A1 (en) | Compositions and methods for treating, ameliorating, and/or preventing viral infections | |
| US20220040338A1 (en) | Alpha Emitter Compositions And Methods | |
| AU2020365736B2 (en) | Peptide-nucleic acid complex having blood-brain barrier penetration ability and composition comprising same | |
| US20250082765A1 (en) | Molecules as anticancer agents for targeted treatment of breast and prostate cancer | |
| US20250360157A1 (en) | Cytotoxic fluoropyrimidine polymers and methods of use thereof |